What Might Hinder Immunotherapies for Skin Cancer
Freiburg Researchers Discover Phagocytes Linked to Exhausted T Cells and Treatment Failure / Findings Could Help Better Predict the Success of Immunotherapies
The reason why immunotherapy does not work in some people with melanoma could also be related to the environment surrounding the tumor cells. Researchers at the Medical Center – University of Freiburg frequently found certain immune system phagocytes in the immediate vicinity of exhausted T cells in patients who did not respond to therapy. These T cells were impaired in their ability to attack cancer cells. The spatial proximity suggests that the phagocytes could be impairing the immune response within the tumor. However, it is not yet clear whether they actually inhibit the T cells. The findings could help better predict responses to immunotherapies in the future. The study was published on November 3, 2026, in the journal Genome Medicine.
“We were able to show that it is not only the cancer cells themselves that are decisive. The tumor’s immediate surroundings also provide important clues as to whether immunotherapy can be successful,” explains Prof. Dr. Dr. Melanie Börries, director of the Institute of Medical Bioinformatics and Systems Medicine at the Medical Center – University of Freiburg and a researcher at the Freiburg partner site of the German Consortium for Translational Cancer Research (DKTK). Börries is also a member of the Cluster of Excellence “Centre for Integrative Biological Signaling Studies” at the University of Freiburg.
Two Different Patterns in the Tumor
In collaboration with the Department of Dermatology and Venereology and the Department of Medicine II, the research team investigated the tumor microenvironment. In the process, the scientists identified specific phagocytes known as lipid-associated tumor-associated macrophages (LA-TAMs). These were more common in patients who did not respond to treatment and were often found adjacent to exhausted T cells. They may contribute to an environment in which T cells are less able to fight cancer cells.
In contrast, in patients who responded to treatment, interferon-activated macrophages were more frequently found alongside active T cells. The spatial analyses included samples from six patients. Using additional data from 334 patients, the team examined the association between high numbers of LA-TAMs, poorer treatment response, and less favorable survival outcomes.
New Possibilities for Cancer Therapy
“Our goal is to derive reliable guidance for treatment decisions from these cellular patterns. This would allow us to identify earlier in the future which patients are likely to benefit most from immunotherapy,” says Börries. Further research is needed before these patterns can be applied in clinical practice. In particular, it must be clarified whether the LA-TAMs themselves contribute to treatment resistance or are merely an indicator of other processes within the tumor.
Original title: Cellular and spatial continuum of TAM functional states governs immune exclusion and dictates immune checkpoint resistance in melanoma
DOI: 10.1186/s13073-026-01794-9
Back
Medical Center - University of Freiburg
Central Information
Phone: 0761 270-0
info@uniklinik-freiburg.de
For press inquiries:
Corporate Communications
Breisacher Straße 153
79110 Freiburg
Phone: 0761 270-84830
kommunikation@uniklinik-freiburg.de
